Ocular inflammatory diseases associated with rheumatoid arthritis

Nature Reviews Rheumatology

Volumn 10, Issue 2, 2014, Pages 108-116

  Artifoni, Mathieu ^a   Rothschild, Pierre Raphaël ^a   Brézin, Antoine ^a   Guillevin, Loïc ^a   Puéchal, Xavier ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENAL CORTEX HORMONES; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; COMORBIDITY; CORNEAL ULCER; HUMANS; INFLAMMATION; PROGNOSIS; SCLERITIS;

EID: 84895900225     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.185     Document Type: Review

References (68)

1. Moreland, L. W. & Curtis, J. R. Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. Semin. Arthritis Rheum. 39, 132-143 (2009).
2. Antero, D. C., Parra, A. G. M., Miyazaki, F. H., Gehlen, M. & Skare, T. L. Secondary Sjögren's syndrome and disease activity of rheumatoid arthritis. Rev. Assoc. Med. Bras. 57, 319-322 (2011).
3. Sainz de la Maza, M. et al. Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology 119, 43-50 (2012).
4. Jabs, D. A., Mudun, A., Dunn, J. P. & Marsh, M. J. Episcleritis and scleritis: clinical features and treatment results. Am. J. Ophthalmol. 130, 469-476 (2000).
5. Galor, A. & Thorne, J. E. Scleritis and peripheral ulcerative keratitis. Rheum. Dis. Clin. North Am. 33, 835-854 (2007).
6. Stewart, R. H. & Kimbrough, R. L. Intraocular pressure response to topically administered fluorometholone. Arch. Ophthalmol. 97, 2139-2140 (1979).
7. Smith, J. R., Mackensen, F. & Rosenbaum, J. T. Therapy insight: scleritis and its relationship to systemic autoimmune disease. Nat. Clin. Pract. Rheumatol. 3, 219-226 (2007).
8. Akpek, E. K., Thorne, J. E., Qazi, F. A., Do, D. V. & Jabs, D. A. Evaluation of patients with scleritis for systemic disease. Ophthalmology 111, 501-506 (2004).
9. Puéchal, X. et al. Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum. 38, 1618-1629 (1995).
10. Erhardt, C. C., Mumford, P. A., Venables, P. J. & Maini, R. N. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann. Rheum. Dis. 48, 7-13 (1989).
11. Foster, C. S., Forstot, S. L. & Wilson, L. A. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology 91, 1253-1263 (1984).
12. Watson, P. G. & Hayreh, S. S. Scleritis and episcleritis. Br. J. Ophthalmol. 60, 163-191 (1976).
13. Watson, P. G., Hazleman, B. L., McCluskey, P. & Pavésio, C. E. The Sclera and Systemic Disorders 153-180 (JP Medical Ltd, London, 2012).
14. Fong, L. P., Sainz de la Maza, M., Rice, B. A., Kupferman, A. E. & Foster, C. S. Immunopathology of scleritis. Ophthalmology 98, 472-479 (1991).
15. Bernauer, W., Watson, P. G., Daicker, B. & Lightman, S. Cells perpetuating the inflammatory response in scleritis. Br. J. Ophthalmol. 78, 381-385 (1994).
16. Di Girolamo, N., Lloyd, A., McCluskey, P., Filipic, M. & Wakefield, D. Increased expression of matrix metalloproteinases in vivo in scleritis tissue and in vitro in cultured human scleral fibroblasts. Am. J. Pathol. 150, 653-666 (1997).
17. Lin, P., Bhullar, S. S., Tessler, H. H. & Goldstein, D. A. Immunologic markers as potential predictors of systemic autoimmune disease in patients with idiopathic scleritis. Am. J. Ophthalmol. 145, 463-471 (2008).
18. Demoruelle, D. et al. Performance of anti-cyclic citrullinated peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease. Arthritis Rheum. 65, 2243-2252 (2013).
19. Jabs, D. A. et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am. J. Ophthalmol. 130, 492-513 (2000).
20. Sainz de la Maza, M.et al. Scleritis therapy. Ophthalmology 119, 51-58 (2012).
21. Messmer, E. M. & Foster, C. S. Destructive corneal and scleral disease associated with rheumatoid arthritis. Medical and surgical management. Cornea 14, 408-417 (1995).
22. Pujari, S. S.et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 117, 356-365 (2010).
23. Jachens, A. W. & Chu, D. S. Retrospective review of methotrexate therapy in the treatment of chronic, noninfectious, nonnecrotizing scleritis. Am. J. Ophthalmol. 145, 487-492 (2008).
24. Galor, A. et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 115, 1826-1832 (2008).
25. Sen, H. N. et al. Mycophenolate mofetil for the treatment of scleritis. Ophthalmology 110, 1750-1755 (2003).
26. Sobrin, L., Christen, W. & Foster, C. S. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology 115, 1416-1421 (2008).
27. Thorne, J. E. et al. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 112, 1472-1477 (2005).
28. Doctor, P. et al. Infliximab for the treatment of refractory scleritis. Br. J. Ophthalmol. 94, 579-583 (2010).
29. Smith, J. R. et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 45, 252-257 (2001).
30. Murphy, C. C. et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111, 352-356 (2004).
31. Atchia, I. I., Kidd, C. E. & Bell, R. W. D. Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. J. Clin. Rheumatol. 12, 291-293 (2006).
32. Ashok, D., Ayliffe, W. H. & Kiely, P. D. W. Necrotizing scleritis associated with rheumatoid arthritis: long-term remission with high-dose infliximab therapy. Rheumatology (Oxford) 44, 950-951 (2005).
33. Botsios, C., Sfriso, P., Ostuni, P. A., Todesco, S. & Punzi, L. Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases. Rheumatology (Oxford) 46, 1042-1043 (2007).
34. Chauhan, S., Kamal, A, Thompson, R. N., Estrach, C. & Moots, R. J. Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br. J. Ophthalmol. 93, 984-985 (2009).
35. Albert, M., Beltrán, E. & Martínez-Costa, L. Rituximab in rheumatoid arthritis-associated peripheral ulcerative keratitis [Spanish]. Arch. Soc. Esp. Oftalmol. 86, 118-120 (2011).
36. Iaccheri, B. et al. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul. Immunol. Inflamm. 18, 223-225 (2010).
37. Sainz de la Maza, M., Foster, C. S., Jabbur, N. S. & Baltatzis, S. Ocular characteristics and disease associations in scleritis-associated peripheral keratopathy. Arch. Ophthalmol. 120, 15-19 (2002).
38. McKibbin, M., Isaacs, J. D. & Morrell, A. J. Incidence of corneal melting in association with systemic disease in the Yorkshire region, 1995- Br. J. Opthalmol. 83, 941-943 (1999).
39. Squirrell, D. M., Winfield, J. & Amos, R. S. Peripheral ulcerative keratitis 'corneal melt' and rheumatoid arthritis: a case series. Rheumatology (Oxford) 38, 1245-1248 (1999).
40. Murray, P. I. & Rahi, A. H. Pathogenesis of Mooren's ulcer: some new concepts. Br. J. Ophthalmol. 68, 182-187 (1984).
41. Messmer, E. M. & Foster, C. S. Vasculitic peripheral ulcerative keratitis. Surv. Ophthalmol. 43, 379-396 (1999).
42. John, S. L., Morgan, K., Tullo, A. B. & Holt, P. J. Corneal autoimmunity in patients with peripheral ulcerative keratitis (PUK) in association with rheumatoid arthritis and Wegener's granulomatosis. Eye (Lond.) 6, 630-636 (1992).
43. Dana, M. R., Qian, Y. & Hamrah, P. Twentyfiveyear panorama of corneal immunology: emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection.
44. Riley, G. P., Harrall, R. L., Watson, P. G., Cawston, T. E. & Hazleman, B. L. Collagenase (MMP-1) and TIMP-1 in destructive corneal disease associated with rheumatoid arthritis. Eye (Lond.) 9, 703-718 (1995).
45. Smith, V. A., Rishmawi, H., Hussein, H. & Easty, D. L. Tear film MMP accumulation and corneal disease. Br. J. Ophthalmol. 85, 147-153 (2001).
46. Clewes, A. R., Dawson, J. K., Kaye, S. & Bucknall, R. C. Peripheral ulcerative keratitis in rheumatoid arthritis: successful use of intravenous cyclophosphamide and comparison of clinical and serological characteristics. Ann. Rheum. Dis. 64, 961-962 (2005).
47. Thomas, J. W. & Pflugfelder, S. C. Therapy of progressive rheumatoid arthritis-associated corneal ulceration with infliximab. Cornea 24, 742-744 (2005).
48. Antao, S. F., Ayoub, T., Tahir, H. & Parmar, D. N. Stabilization of bilateral progressive rheumatoid corneal melt with infliximab. Case Rep. Ophthalmol. Med.2012, 173793 (2012).
49. Silva, B. L. et al. Peripheral ulcerative keratitis: a serious complication of rheumatoid arthritis. Rheumatol. Int. 30, 1267-1268 (2010).
50. Vitali, C., Moutsopoulos, H. M. & Bombardieri, S. The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome. Ann. Rheum. Dis. 53, 637-647 (1994).
51. Andonopoulos, A. P., Drosos, A. A., Skopouli, F. N., Acritidis, N. C. & Moutsopoulos, H. M. Secondary Sjögren's syndrome in rheumatoid arthritis. J. Rheumatol. 14, 1098-1103 (1987).
52. Uhlig, T., Kvien, T. K., Jensen, J. L. & Axéll, T. Sicca symptoms, saliva and tear production, and disease variables in 636 patients with rheumatoid arthritis. Ann. Rheum. Dis. 58, 415-422 (1999).
53. Brun, J. G., Madland, T. M. & Jonsson, R. A prospective study of sicca symptoms in patients with rheumatoid arthritis. Arthritis Rheum. 49, 187-192 (2003).
54. Piper, H. et al. Prevalence and predictors of ocular manifestations of RA: is there a need for routine screening? Musculoskeletal. Care 5, 102-117 (2007).
55. Lemp, M. A. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J. 21, 221-232 (1995).
56. Vivino, F. B. et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch. Intern. Med. 159, 174-181 (1999).
57. US Department of Health & Human Services. Salogen® Tablets. US Food and Drug Administration [online], http://www.accessdata.fda.gov/drugsatfda- docs/label/2003/020237s012lbl.pdf (2013).
58. Akpek, E. K. et al. Treatment of Sjögren's syndrome-associated dry eye an evidence-based review. Ophtalmology 118, 1242-1252 (2011).
59. US Department of Health & Human Services. Restasis®. US Food and Drug Administration [online], http://www.accessdata.fda.gov/drugsatfda-docs/ label/2012/050790s020lbl.pdf (2013).
60. Kruh, J. N., Yang, P., Suelves, A. M. & Foster, C. S. Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up. Opthalmology http://dx.doi.org/1016/j.ophtha.2
61. Guignard, S. et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann. Rheum. Dis. 65, 1631-1634 (2006).
62. Rudwaleit, M. et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann. Rheum. Dis. 68, 696-701 (2009).
63. Sieper, J. et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann. Rheum. Dis. 69, 226-229 (2010).
64. Braun, J., Baraliakos, X., Listing, J. & Sieper, J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 52, 2447-2451 (2005).
65. Wendling, D. et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin. Arthritis Rheum. 41, 503-510 (2011).
66. Sfikakis, P. P. The first decare of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr. Dir. Autoimmun. 11, 180-210 (2010).
67. Wendling, D., Dernis, E., Prati, C., Frisch, E. & Delbosc, B. Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect? J. Rheumatol. 38, 2284 (2011).
68. Goodisson, L.A., Bourne, J. T. & Maharajan, S. A case of bilateral peripheral ulcerative keratitis following treatment with rituximab. Rheumatology (Oxford) 49, 609-610 (2010)